NOTE, original article title: Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA

Findings in a large prospective juvenile idiopathic arthritis (JIA) patient registry demonstrated an approximately threefold elevated risk of psoriasis following tumor necrosis factor inhibitors (TNFi) exposure.

• De-identified data from the CARRA (Childhood Arthritis and Rheumatology Research Alliance) Registry were used to determine the association between TNFi therapy and the onset of new psoriasis in children with JIA.

• In this study, 8,225 patients were observed for a median follow-up of 3.9 years, and over half of the patients were prescribed TNFi (n=4,437, 54%).

• For new onset of psoriasis after ever exposure to TNFi, the estimated adjusted HR was 2.93 (2.15 to 3.98).

• Children ever receiving and actively receiving adalimumab were found to have the highest incidence rate of psoriasis.

• A lower risk was observed in relation to ever concurrent methotrexate use (HR 0.45, 0.29 to 0.69).